|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12345678910111213...5253» |
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial completion, Enrollment change: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=48, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=90 --> 48
- || CYAD-01 / Celdara Medical, Celyad Oncology
Trial completion, Trial primary completion date, Metastases: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) - Jun 3, 2018
P1, N=12, Completed, Sponsor: Celyad (formerly named Cardio3 BioSciences)
Active, not recruiting --> Completed | N=90 --> 48 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018 Active, not recruiting --> Completed
- | Rydapt (midostaurin) / Novartis
Enrollment change, Trial termination, Combination therapy: Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P2, N=13, Terminated, Sponsor: David Iberri
Active, not recruiting --> Completed N=36 --> 13 | Recruiting --> Terminated; Accrual factor
- | Enrollment change, Trial termination: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P1, N=17, Terminated, Sponsor: Stanford University
N=36 --> 13 | Recruiting --> Terminated; Accrual factor N=30 --> 17 | Recruiting --> Terminated; Accrual factor
- | Trial completion, Trial completion date: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 1, 2018
P1, N=24, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=30 --> 17 | Recruiting --> Terminated; Accrual factor Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018
- | adavosertib (AZD1775) / AstraZeneca, Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change, Trial termination, Combination therapy: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - May 30, 2018
P1, N=20, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> May 2018 N=30 --> 20 | Active, not recruiting --> Terminated
- ||| guadecitabine (SGI-110) / Otsuka
Trial completion: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - May 4, 2018
P2, N=56, Completed, Sponsor: Groupe Francophone des Myelodysplasies
N=30 --> 20 | Active, not recruiting --> Terminated Active, not recruiting --> Completed
- | imatinib / Generic mfg., cytarabine / Generic mfg.
Trial completion: Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - May 3, 2018
P3, N=1551, Completed, Sponsor: Heidelberg University
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels (clinicaltrials.gov) - May 1, 2018
P=N/A, N=397, Completed, Sponsor: Medtronic Spinal and Biologics
Recruiting --> Completed Active, not recruiting --> Completed
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Trial completion date, Trial primary completion date, Post-transplantation: PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (clinicaltrials.gov) - Apr 30, 2018
P1/2, N=20, Active, not recruiting, Sponsor: St. Petersburg State Pavlov Medical University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- Farydak (panobinostat) / Secura Bio
Trial completion date, Combination therapy, Epigenetic controller, Metastases: Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 25, 2018
P1, N=29, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Dec 2017 --> Dec 2018
- | imatinib / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ (clinicaltrials.gov) - Apr 25, 2018
P3, N=680, Suspended, Sponsor: Junmin Li
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Dec 2017 --> Dec 2018 | Enrolling by invitation --> Suspended | Trial primary completion date: Dec 2016 --> Dec 2018
- ||||||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: SPIRIT2: Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (clinicaltrials.gov) - Apr 24, 2018
P3, N=814, Completed, Sponsor: Newcastle University
Trial completion date: Dec 2017 --> Dec 2018 | Enrolling by invitation --> Suspended | Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Completed | Trial completion date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2017 --> Mar 2018
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Enrollment open, Trial completion date, Trial primary completion date: A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (clinicaltrials.gov) - Apr 20, 2018
P1/2, N=25, Recruiting, Sponsor: Cell Medica Ltd
Recruiting --> Completed | Trial completion date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2017 --> Mar 2018 Suspended --> Recruiting | Trial completion date: Dec 2018 --> Jul 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Enrollment open, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Apr 19, 2018
P1/2, N=18, Recruiting, Sponsor: Cell Medica Ltd
Suspended --> Recruiting | Trial completion date: Dec 2018 --> Jul 2019 | Trial primary completion date: Dec 2018 --> Jul 2019 Suspended --> Recruiting
- | melphalan / Generic mfg., fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=3, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Suspended --> Recruiting Trial completion date: May 2018 --> Oct 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Oct 2017; Closed due to poor accrual
- ||| gandotinib (LY 2784544) / Eli Lilly
Trial completion, Trial completion date: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Apr 17, 2018
P1, N=80, Completed, Sponsor: Eli Lilly and Company
Trial completion date: May 2018 --> Oct 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Oct 2017; Closed due to poor accrual Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2018
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Enrollment change: Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 13, 2018
P1/2, N=2, Terminated, Sponsor: University of Nebraska
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2018 N=33 --> 2
- | cytarabine / Generic mfg., decitabine / Generic mfg.
Trial completion, Enrollment change, Metastases: Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (clinicaltrials.gov) - Apr 13, 2018
P=N/A, N=12, Completed, Sponsor: University of Washington
N=33 --> 2 Active, not recruiting --> Completed | N=30 --> 12
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion date: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (clinicaltrials.gov) - Apr 10, 2018
P2, N=9, Terminated, Sponsor: Sherif S. Farag
Active, not recruiting --> Completed | N=30 --> 12 Trial completion date: May 2016 --> Jul 2017
- Trial completion date, Trial primary completion date, IO biomarker: A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 9, 2018
P1/2, N=40, Recruiting, Sponsor: Opsona Therapeutics Ltd.
Trial completion date: May 2016 --> Jul 2017 Trial completion date: Jun 2018 --> Apr 2019 | Trial primary completion date: Jun 2018 --> Apr 2019
- | Trial completion, Trial completion date, Trial primary completion date: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (clinicaltrials.gov) - Apr 6, 2018
P2, N=279, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial completion date: Jun 2018 --> Apr 2019 | Trial primary completion date: Jun 2018 --> Apr 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017
- | zoledronic acid / Generic mfg.
Trial completion date, Trial primary completion date, Head-to-Head: Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 6, 2018
P4, N=280, Not yet recruiting, Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Aug 2018 --> Oct 2017 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Apr 2018 --> Sep 2020
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial completion date, Trial primary completion date: Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (clinicaltrials.gov) - Apr 5, 2018
P1/2, N=9, Recruiting, Sponsor: Stanford University
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Apr 2018 --> Sep 2020 Trial completion date: Feb 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Aug 2018
- ||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion date: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) (clinicaltrials.gov) - Apr 4, 2018
P3, N=222, Active, not recruiting, Sponsor: Incyte Corporation
Trial completion date: Feb 2018 --> Aug 2018 | Trial primary completion date: Feb 2018 --> Aug 2018 Trial completion date: Mar 2018 --> Sep 2018
- Daurismo (glasdegib) / Pfizer
Enrollment change, Trial termination: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (clinicaltrials.gov) - Apr 2, 2018
P2, N=21, Terminated, Sponsor: Pfizer
Trial completion date: Mar 2018 --> Sep 2018 N=222 --> 21 | Recruiting --> Terminated
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 31, 2018
P1, N=10, Terminated, Sponsor: University of Southern California
N=222 --> 21 | Recruiting --> Terminated N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual
- | Phase classification: Genetic Analysis of Gray Platelet Syndrome (clinicaltrials.gov) - Mar 30, 2018
P, N=123, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual Phase classification: P=N/A --> P
- || azacitidine / Generic mfg.
Trial completion date: Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 30, 2018
P2, N=72, Active, not recruiting, Sponsor: Celgene
Phase classification: P=N/A --> P Trial completion date: Feb 2017 --> Mar 2018
- | Trial completion: PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (clinicaltrials.gov) - Mar 22, 2018
P=N/A, N=99, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial completion date: Feb 2017 --> Mar 2018 Recruiting --> Completed
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Minimal residual disease: Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 21, 2018
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: MDS04: Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 19, 2018
P=N/A, N=349, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jun 2017 | Trial primary completion date: Dec 2017 --> Jun 2017
- Erivedge (vismodegib) / Roche
Trial completion, Phase classification, Combination therapy: A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=10, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jun 2017 | Trial primary completion date: Dec 2017 --> Jun 2017 Terminated --> Completed | Phase classification: P1 --> P1/2
- | Januvia (sitagliptin) / Merck (MSD)
Trial completion, Trial completion date: Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (clinicaltrials.gov) - Mar 14, 2018
P2, N=19, Completed, Sponsor: Sherif S. Farag
Terminated --> Completed | Phase classification: P1 --> P1/2 Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017
- | Qinprezo (vosaroxin) / Denovo
Trial completion, Trial completion date, Trial primary completion date: Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy (clinicaltrials.gov) - Mar 14, 2018
P1/2, N=40, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | Trial completion date: Nov 2018 --> Dec 2017 Active, not recruiting --> Completed | Trial completion date: May 2019 --> Feb 2018 | Trial primary completion date: Oct 2018 --> Feb 2018
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial withdrawal: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (clinicaltrials.gov) - Mar 14, 2018
P2, N=0, Withdrawn, Sponsor: Jazz Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Feb 2018 | Trial primary completion date: Oct 2018 --> Feb 2018 Recruiting --> Withdrawn
- |||| tosedostat (CHR-2797) / SOBI
Trial completion, Trial completion date, Trial primary completion date: Study of Clinical Efficacy and Safety of Tosedostat in MDS (clinicaltrials.gov) - Mar 14, 2018
P2, N=80, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Withdrawn Recruiting --> Completed | Trial completion date: Mar 2021 --> Oct 2017 | Trial primary completion date: Mar 2018 --> Oct 2017
- | imatinib / Generic mfg.
Trial completion: STIM 2: Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (clinicaltrials.gov) - Mar 13, 2018
P=N/A, N=220, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | Trial completion date: Mar 2021 --> Oct 2017 | Trial primary completion date: Mar 2018 --> Oct 2017 Active, not recruiting --> Completed
- | riluzole / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) (clinicaltrials.gov) - Mar 8, 2018
P3, N=270, Active, not recruiting, Sponsor: AOSpine North America Research Network
Active, not recruiting --> Completed Trial completion date: Mar 2018 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2018
- | gandotinib (LY 2784544) / Eli Lilly
Trial completion date: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Mar 6, 2018
P1, N=80, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Mar 2018 --> Apr 2018 | Trial primary completion date: Jan 2018 --> Apr 2018 Trial completion date: Aug 2018 --> Dec 2019
- || guadecitabine (SGI-110) / Otsuka
Trial completion date: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - Mar 3, 2018
P2, N=56, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Trial completion date: Aug 2018 --> Dec 2019 Trial completion date: Feb 2018 --> Apr 2018
- | decitabine / Generic mfg.
Trial completion date: DECI2009: Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Mar 3, 2018
P2, N=41, Active, not recruiting, Sponsor: Fondazione Italiana Sindromi Mielodisplastiche Onlus
Trial completion date: Feb 2018 --> Apr 2018 Trial completion date: Dec 2017 --> Jun 2018
- | Trial completion: MICROFANC: Microcephaly Genetic Deficiency in Neural Progenitors (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=98, Completed, Sponsor: Assistance Publique - H
Trial completion date: Dec 2017 --> Jun 2018 Recruiting --> Completed
- ||||||| Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Trial completion, Trial completion date, Trial primary completion date: The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML (clinicaltrials.gov) - Feb 27, 2018
P3, N=400, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2017 | Trial completion date: Sep 2016 --> Dec 2017
- vorasidenib (S95032) / Servier
Trial completion date, Trial primary completion date, Metastases: Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (clinicaltrials.gov) - Feb 26, 2018
P1, N=46, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2017 | Trial completion date: Sep 2016 --> Dec 2017 Trial primary completion date: Dec 2017 --> Mar 2018 | Trial completion date: Apr 2018 --> Mar 2018
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. (clinicaltrials.gov) - Feb 22, 2018
P2, N=23, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Mar 2018 | Trial completion date: Apr 2018 --> Mar 2018 Recruiting --> Completed | N=60 --> 23 | Trial completion date: May 2017 --> Mar 2017 | Trial primary completion date: May 2017 --> Mar 2017
- cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
Trial termination: POE07-01: Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (clinicaltrials.gov) - Feb 15, 2018
P1, N=35, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=60 --> 23 | Trial completion date: May 2017 --> Mar 2017 | Trial primary completion date: May 2017 --> Mar 2017 Active, not recruiting --> Terminated; Lack of accrual
- Coversin SC (nomacopan SC) / Akari Therap
Enrollment closed, Trial primary completion date: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (clinicaltrials.gov) - Feb 15, 2018
P2, N=6, Active, not recruiting, Sponsor: AKARI Therapeutics
Active, not recruiting --> Terminated; Lack of accrual Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Feb 2018
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML (clinicaltrials.gov) - Feb 14, 2018
P1/2, N=49, Active, not recruiting, Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Feb 2018 --> Dec 2018